PERSONALISING ANTICANCER DRUG COMBINATIONS
Cancer Research has led to the development of a new type of anticancer agents called "targeted molecules" which aim to specifically target a particular protein. They are generaly administered in combination with cytotoxic drugs which create DNA damage potentially leading to cell death. Our Research focuses on developping mathematical models ale to predict optimal drug combinations fro each individual patient. Those models are informed by multiple datasets measured in individual patients including tumor multi-omics information.
IN SILICO CLINICAL TRIAL
Mathematical models may allow to guide patient selection in classical clinical trials testing a fixed drug combinations. They also offer the opportunity of a new type of clinicial trials in which patients would receive personalised drug combinations predicted as optimal by the models.
